BridgeBio Pharma (BBIO) Capital Expenditures Growth (1y) (2019 - 2025)
BridgeBio Pharma (BBIO) Capital Expenditures Growth (1y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 143.40% |
| 10 | BridgeBio Pharma | 16.52 Bn | 15.58 Bn | 184.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21,600.00% |
| Sep 30, 2025 | -94.12% |
| Dec 31, 2024 | 105.43% |
| Sep 30, 2024 | 182.26% |
| Jun 30, 2024 | -246.03% |
| Mar 31, 2024 | 5,691.67% |
| Dec 31, 2023 | -101.93% |
| Sep 30, 2023 | 92.25% |
| Jun 30, 2023 | -82.95% |
| Mar 31, 2023 | -98.40% |
| Dec 31, 2022 | -55.90% |
| Sep 30, 2022 | -77.93% |
| Jun 30, 2022 | 2.03% |
| Mar 31, 2022 | -58.03% |
| Dec 31, 2021 | 300.99% |
| Sep 30, 2021 | -427.69% |
| Jun 30, 2021 | 611.27% |
| Mar 31, 2021 | -60.08% |
| Dec 31, 2020 | -407.50% |
| Sep 30, 2020 | 44.09% |